证券代码：300595 证券简称：欧普康视 2023 年 6 月 5 日投资者关系活动记录表 编号：2023-005 | --- | --- | --- | |--------|---------------|-------------| | | ☑特定对象调研 | □分析师会议 | | 投资者 | | | | | □媒体采访 | □业绩说明会 | | 关系活 | | | | | □新闻发布会 | □路演活动 | | 动类别 | | | | | ☑现场参观 | □在线会议 | 参与单 相聚资本、和谐汇一、汐泰投资、民生加银、嘉合基金、淳厚基金、睿 位人员 郡资产、泰达宏利、聚鸣投资、浙江韶夏、招商证券、广州鑫慧投等 12 家机 情况 构投资人。（排名不分先后） 时间 2023 年 6 月 5 日 15:50-17:10 上市公 董事长兼总经理陶悦群博士 司参会 董事、副总经理兼董秘施贤梅女士 人员 董事、财务总监卫立治先生 交流 环节 董事长就投资者提出的问题进行交流。 Q：未来河北集采对公司产品销售的影响，河北集采是否会在各省出现联 动，未来的价格趋势是怎样的？ 投资者关 系活动交 A：河北集采投标的报价正 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 401,473,749.24, representing an increase of 8.17% compared to the same period last year[3]. - Net profit attributable to shareholders for Q1 2023 was CNY 173,217,878.06, up 16.96% year-on-year[3]. - The net profit excluding non-recurring gains and losses was CNY 149,290,819.27, reflecting an increase of 8.43% compared to the previous year[3]. - The total operating revenue for Q1 2023 was CNY 401,473,749.24, an increase of 8.4% compared to CNY 371,150,930.09 in Q1 2022[26]. - The total profit for Q1 2023 was approximately ¥230.45 million, an increase from ¥185.84 million in Q1 2022, representing a growth of about 24%[28]. - The net profit for Q1 2023 reached approximately ¥197.64 million, compared to ¥163.41 million in the same period last year, marking an increase of around 21%[28]. - Basic earnings per share for Q1 2023 were ¥0.1940, up from ¥0.1744 in Q1 2022, reflecting a growth of approximately 11%[29]. - The company's total comprehensive income for Q1 2023 was approximately ¥197.64 million, compared to ¥163.41 million in Q1 2022, showing an increase of around 21%[28]. - The net profit attributable to the parent company for Q1 2023 was approximately ¥173.22 million, up from ¥148.10 million in Q1 2022, indicating a growth of about 17%[28]. Cash Flow and Financing - The net cash flow from operating activities was CNY 192,191,357.35, which is a 21.07% increase from the same period last year[3]. - Cash flow from operating activities for Q1 2023 was approximately ¥192.19 million, compared to ¥158.75 million in Q1 2022, indicating an increase of about 21%[31]. - Total cash inflow from financing activities decreased by 90.87% to ¥4,676,000.00, primarily due to the absence of equity incentive plan investment funds received in the same period last year[16]. - Total cash outflow from financing activities decreased by 31.17% to ¥23,538,056.86, mainly due to reduced lease payments and dividends paid to minority shareholders[16]. - Net cash flow from financing activities turned negative at -¥18,862,056.86, a decline of 210.84% compared to the previous year, attributed to the lack of equity incentive plan investment funds[16]. - The net cash flow from financing activities for Q1 2023 was approximately -¥18.86 million, compared to ¥17.02 million in Q1 2022, indicating a significant change in financing strategy[32]. Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 5,382,768,238.63, marking a 5.16% increase from the end of the previous year[3]. - Total current assets rose to ¥3,885,653,429.76, up from ¥3,769,238,489.78, indicating an increase of about 3.1%[23]. - Long-term equity investments increased to ¥451,820,701.87 from ¥381,460,072.17, representing a growth of approximately 18.4%[23]. - The company's total liabilities amounted to CNY 574,839,914.04, up from CNY 523,048,227.89, reflecting a rise of 9.9%[25]. - The equity attributable to shareholders increased to CNY 4,404,629,254.26 from CNY 4,230,206,261.41, showing a growth of 4.1%[25]. Operational Efficiency - The total operating costs decreased to CNY 194,230,834.44 from CNY 196,126,226.70, reflecting a reduction of 1% year-over-year[27]. - Operating profit for Q1 2023 was CNY 231,054,020.43, up from CNY 185,693,212.41 in the same period last year, representing a growth of 24.5%[27]. - The company reported a net profit margin improvement, with net profit increasing significantly due to higher operating efficiency[27]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 67,979, with the top ten shareholders holding a combined 56.27% of shares[18]. - Tao Yuequn, a natural person, holds 33.40% of shares, amounting to 298,890,828 shares[18]. Future Outlook - The company expects the trend of order growth to continue into Q2 2023 as business operations return to normal[8]. - Future outlook includes plans for market expansion and potential new product launches to drive further revenue growth[27]. Research and Development - Research and development expenses for Q1 2023 were CNY 7,861,038.77, slightly down from CNY 8,887,583.69 in Q1 2022[27]. - The company has not disclosed any new product or technology developments in the current report[21]. - There are no significant mergers or acquisitions reported during this period[21].

Sales and Market Performance - Q1 2023 sales of OK lenses and care products improved significantly compared to Q4 2022, with a shift from decline to growth [2] - 47.4% of 2022 revenue came from terminal business, with over 300 terminals under company control [6] - OK lens market penetration is low due to concentration in large hospitals, limited service availability in smaller cities, and high consumer cost requirements [6] Product Development and Innovation - New product lines include reduced defocus glasses, red light eye care lamps, next-generation OK lenses, scleral lenses, and light therapy devices [4] - Next-generation OK lenses expected to complete clinical trials and submit registration in 2023 [4] - Scleral lenses address traditional RGP limitations and have significant application potential in China [4] Terminal Expansion Strategy - Company plans to expand terminal network through both new construction and acquisitions, prioritizing success rate over quantity [5] - Terminal expansion expected to significantly outperform 2022 results [3] - Regional terminal construction and management centers established to oversee investment and development [3] Industry Trends and Competitive Advantage - Non-medical system expected to remain mainstream for OK lens sales despite potential hospital channel growth through centralized procurement [3] - Future eye care terminal channels predicted to follow developed country models with both hospital-based and community-based clinics [3] - Company maintains comprehensive competitive advantages in R&D, brand, sales network, partnerships, and talent development [4] Financial and Investment Activities - Company participated in establishing new investment funds (Yingfeinidi and Shanlan) to expand investment scale and improve quality [6] - Industrial fund investments have shown success, with participation in USTC Silicon Valley platform company [6] Production Capacity - Two new OK lens production lines in debugging phase, expected to start production next month [6] - Two additional production lines planned for year-end completion [6] - Production capacity expansion typically occurs during off-peak seasons (summer and winter breaks) [6]

Financial Performance - The company reported a significant increase in revenue for the fiscal year 2022, reaching RMB 1.2 billion, representing a growth of 25% compared to the previous year[29]. - The company's operating revenue for 2022 was CNY 1,525,319,073.48, representing a 17.78% increase compared to CNY 1,295,045,844.66 in 2021[36]. - The net profit attributable to shareholders for 2022 was CNY 623,736,142.43, a 12.44% increase from CNY 554,737,175.25 in 2021[36]. - The net profit after deducting non-recurring gains and losses was CNY 559,536,222.36, up 14.69% from CNY 487,880,651.30 in 2021[36]. - The total assets at the end of 2022 reached CNY 5,118,535,972.11, a 72.20% increase from CNY 2,972,426,471.10 at the end of 2021[36]. - The company reported a basic earnings per share of CNY 0.7164 for 2022, which is a 9.61% increase from CNY 0.6536 in 2021[36]. - The cash flow from operating activities for 2022 was CNY 651,716,838.98, reflecting a 3.43% increase from CNY 630,094,069.84 in 2021[36]. - The company achieved a revenue of CNY 1,525,319,073.48 in 2022, representing a growth of 17.78% year-over-year[54]. - The company reported a weighted average return on equity of 25.74% for 2022, down from 28.30% in 2021[36]. Product Development and Innovation - The company plans to expand its business into optometry services and comprehensive vision care products to diversify its revenue streams[10]. - New product development includes the introduction of high oxygen permeability contact lenses, which are expected to capture a larger market share[29]. - The company has allocated RMB 200 million for research and development in advanced optical technologies over the next two years[29]. - The company is developing alternative materials to reduce reliance on imported lens materials, mitigating risks associated with trade policy changes[8]. - The company has launched several safety auxiliary products, including disinfection boxes for hard lens trial sets and real-time monitoring devices for corneal status[66]. - The company has completed clinical trials for new products aimed at high myopia patients, enhancing its market offerings[106]. - The company has developed and launched several new products, including an intelligent amblyopia eye mask and a new type of light therapy product, contributing to its innovation pipeline[74]. - The company is focusing on new product development in the contact lens category, with an expected launch in Q3 2023[130]. Market Expansion and Strategy - The company is actively pursuing market expansion in Southeast Asia, targeting a 15% increase in market penetration by the end of 2023[29]. - The company is transitioning towards becoming a comprehensive eye care product manufacturer and service provider[51]. - The company has outlined a strategic plan for market expansion, targeting underserved areas to increase its customer base[100][101]. - The company plans to enhance distribution and direct sales performance by increasing product offerings, particularly specialty products, and strengthening brand promotion and technical support[153]. - The company is exploring potential acquisitions to strengthen its market position in the optical health sector[128]. - The company has established partnerships with three new investment firms to enhance its funding capabilities[128]. Risks and Challenges - The company reported a significant reliance on orthokeratology lenses, which currently constitute the majority of its sales revenue, indicating a potential risk if competitive products emerge[10]. - The company is currently not included in the medical insurance reimbursement list, which may lead to uncertain impacts on performance if its main products are included in future bulk purchasing policies[7]. - The company is facing risks related to the legal use of its long-term implantable optical devices, which could lead to lawsuits affecting its business and reputation[9]. - The company has a concentrated sales region, with the East China area accounting for a significant portion of total revenue, posing risks if the business environment in that region deteriorates[12]. - The company is facing intensified competition with 8 imported brands and 5 domestic new brands in the market, prompting strategies for product innovation and marketing support[156]. - The company is addressing risks from centralized raw material suppliers by diversifying its supplier base and enhancing its own material production capabilities[156]. Corporate Governance and Management - The company has established a comprehensive internal control system to ensure compliance with laws and regulations, enhancing governance levels[164]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[163]. - The company maintains complete independence in assets, personnel, finance, organization, and business from its controlling shareholder[166]. - The company has a fully independent procurement, production, and sales system, ensuring no reliance on related parties for operations[167]. - The management team includes individuals with extensive experience in various sectors, including healthcare and finance, contributing to strategic decision-making[172][175]. - The company has a strong focus on research and development, with a dedicated R&D director currently in place[173]. Financial Management and Investments - The company raised a total of RMB 150,317.14 million through a private placement of 42,594,826 shares at RMB 35.29 per share[134]. - The company has committed to invest a total of 417.60 million CNY in the contact lens and supporting product industrialization project, with 10.87 million CNY invested by the end of the reporting period, achieving 26.04% of the planned investment[136]. - The company’s financial management includes dedicated accounts for raised funds to ensure proper usage and tracking[135]. - The company has not reported any issues or other situations regarding the use and disclosure of raised funds[137]. - The company’s total investment for the reporting period was approximately ¥218.39 million, a decrease of 4.06% from ¥227.63 million in the previous year[125]. Shareholder Returns - The company plans to distribute cash dividends of 1.4 yuan per 10 shares to all shareholders, based on a total of 894,826,637 shares[15]. - The proposed cash dividend is RMB 1.40 per 10 shares, totaling RMB 125,275,729.18[198]. - The cash dividend represents 100% of the total profit distribution amount[198]. - The decision-making process for profit distribution involved independent directors and considered the opinions of minority shareholders[197]. - The company has complied with all regulatory requirements regarding cash dividend policies[197].